Damora Therapeutics, Inc. is trading 5.9% up today at $21.34 following bullish analyst coverage and price targets significantly higher than current levels.
- HC Wainwright initiated coverage with a Buy rating and a $45 price target, while other firms have set targets in the $35–$51 range.
- Analysts highlighted optimism surrounding the company’s drug pipeline and long-term growth potential, despite its current unprofitable status.